Schering-Plough's chief executive says the approval of Vytorin, a new entrant in the market of cholesterol-lowering drugs, is the key to the future of the company. The approval came at the end of a week when Schering-Plough suffered its fourth consecutive quarterly loss and an expected guilty plea in a $350 million Medicaid fraud suit.

Related Summaries